Literature DB >> 28426902

Hepatic steatosis after pediatric liver transplant.

Emily R Perito1,2, Tabitha Vase3, Rageshree Ramachandran4, Andrew Phelps5, Kuang-Yu Jen6, Robert H Lustig1, Vickie A Feldstein5, Philip Rosenthal1,7.   

Abstract

Hepatic steatosis develops after liver transplantation (LT) in 30% of adults, and nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in nontransplanted children. However, posttransplant steatosis has been minimally studied in pediatric LT recipients. We explored the prevalence, persistence, and association with chronic liver damage of hepatic steatosis in these children. In this single-center study of pediatric patients transplanted 1988-2015 (n = 318), 31% of those with any posttransplant biopsy (n = 271) had ≥ 1 biopsy with steatosis. Median time from transplant to first biopsy with steatosis was 0.8 months (interquartile range [IQR], 0.3-6.5 months) and to last biopsy with steatosis was 5.5 months (IQR, 1.0-24.5 months); 85% of patients with steatosis also had for-cause biopsies without steatosis. All available for-cause biopsies were re-evaluated (n = 104). Of 9 biopsies that could be interpreted as nonalcoholic steatohepatitis (NASH)/borderline NASH, with steatosis plus inflammation or ballooning, 8 also had features of cholestasis or rejection. Among 70 patients with surveillance biopsies 3.6-20.0 years after transplant, only 1 overweight adolescent had a biopsy with NAFLD (grade 1 steatosis, mild inflammation, no ballooning or fibrosis)-despite a 30% prevalence of overweight/obesity in the cohort and 27% with steatosis on previous for-cause biopsy. Steatosis on preceding for-cause biopsy was not associated with portal (P = 0.49) or perivenular fibrosis (P = 0.85) on surveillance biopsy. Hepatic steatosis commonly develops early after transplant in children and adolescents, but it rarely persists. Biopsies that did have steatosis with NASH characteristics were all for-cause, mostly in patients with NAFLD risk factors and/or confounding causes of liver damage. Prospective studies that follow children into adulthood will be needed to evaluate if and when hepatic steatosis presents a longterm risk for pediatric LT recipients. Liver Transplantation 23 957-967 2017 AASLD.
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28426902      PMCID: PMC5604881          DOI: 10.1002/lt.24773

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  22 in total

1.  De novo fatty liver due to vascular complications after liver transplantation.

Authors:  M Zahmatkeshan; B Geramizadeh; A Eshraghian; S Nikeghbalian; A Bahador; H Salahi; S A Malek-Hosseini
Journal:  Transplant Proc       Date:  2011-03       Impact factor: 1.066

2.  Liver allograft pathology in healthy pediatric liver transplant recipients.

Authors:  Andrea Briem-Richter; Rainer Ganschow; Marijke Sornsakrin; Florian Brinkert; Jan Schirmer; Hansjörg Schaefer; Enke Grabhorn
Journal:  Pediatr Transplant       Date:  2013-07-09

3.  Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience.

Authors:  Vicky L Ng; Estella M Alonso; John C Bucuvalas; Geoff Cohen; Christine A Limbers; James W Varni; George Mazariegos; John Magee; Susan V McDiarmid; Ravinder Anand
Journal:  J Pediatr       Date:  2011-12-20       Impact factor: 4.406

4.  2000 CDC Growth Charts for the United States: methods and development.

Authors:  Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Vital Health Stat 11       Date:  2002-05

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.

Authors:  Anneloes E Bohte; Jochem R van Werven; Shandra Bipat; Jaap Stoker
Journal:  Eur Radiol       Date:  2010-07-31       Impact factor: 5.315

7.  Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis.

Authors:  Mélanie Vallin; Olivier Guillaud; Olivier Boillot; Valérie Hervieu; Jean-Yves Scoazec; Jérôme Dumortier
Journal:  Liver Transpl       Date:  2014-09       Impact factor: 5.799

8.  Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children.

Authors:  C Venturi; C Sempoux; J Bueno; J C Ferreres Pinas; C Bourdeaux; J Abarca-Quinones; J Rahier; R Reding
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

9.  Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease.

Authors:  Kathy A Love-Osborne; Kristen J Nadeau; Jeanelle Sheeder; Laura Z Fenton; Phil Zeitler
Journal:  J Adolesc Health       Date:  2008-03-04       Impact factor: 5.012

10.  Low-dose steroids associated with milder histological changes after pediatric liver transplantation.

Authors:  Silja Kosola; Hanna Lampela; Hannu Jalanko; Heikki Mäkisalo; Jouko Lohi; Johanna Arola; Mikko P Pakarinen
Journal:  Liver Transpl       Date:  2013-02       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.